Yes. Extensive scientific evidence and legal verdicts confirm that long-term Roundup exposure is linked to non-Hodgkin’s lymphoma, a type of blood cancer. Over 170,000 lawsuits have been filed against Bayer and Monsanto alleging that glyphosate, the active ingredient in Roundup weedkiller, caused cancer in people who were exposed to the herbicide over many years. A Georgia man who used Roundup for two decades was awarded $2 billion by a jury in April 2025, and since 2023, at least eight juries have returned verdicts totaling over $6 billion against the manufacturer.
The scientific foundation for these claims dates back to 2015, when the International Agency for Research on Cancer (IARC), part of the World Health Organization, classified glyphosate as “probably carcinogenic to humans.” More recent research has found that glyphosate exposure is associated with a 41% increased risk of genetic mutations that lead to non-Hodgkin’s lymphoma. While the EPA maintains that glyphosate is “not likely carcinogenic” at typical exposure levels, this regulatory disagreement with international health agencies has not stopped the courts from awarding billions in damages to plaintiffs. As of July 2026, a $7.25 billion settlement announced by Bayer in February is moving through court approval, with payouts ranging from $6,000 to $165,000 for eligible claimants. Approximately 100,000 claims have already been settled for roughly $11 billion, and thousands more cases remain pending in federal court.
Table of Contents
- What Scientific Evidence Links Roundup Exposure to Non-Hodgkin’s Lymphoma?
- How Strong Is the Scientific Evidence Compared to Regulatory Approval?
- What Are the Current Settlement Payouts and How Much Has Already Been Paid?
- How Many Roundup Lawsuits Are There, and How Many Remain Pending?
- What Did the Supreme Court’s June 2026 Ruling Mean for Pending Roundup Claims?
- What Were the Largest Individual Roundup Cancer Verdicts?
- Who Can Claim the $7.25 Billion Settlement, and What Is the Deadline?
What Scientific Evidence Links Roundup Exposure to Non-Hodgkin’s Lymphoma?
The medical connection between glyphosate and non-Hodgkin’s lymphoma rests on the mechanism of how the herbicide affects cells at the genetic level. A 2021 study found that glyphosate exposure significantly increased the risk of genetic mutations in cells, mutations that are known precursors to non-Hodgkin’s lymphoma development. These mutations can accumulate over years of repeated exposure, which is why people who used Roundup regularly—such as farmers, landscapers, and homeowners who applied it frequently—have shown the highest cancer rates in settlements and verdicts. Non-Hodgkin’s lymphoma is a diverse group of blood cancers affecting the immune system. Unlike Hodgkin’s lymphoma, which follows more predictable patterns, non-Hodgkin’s encompasses dozens of subtypes and can develop in various parts of the body.
This variability is important because it means that glyphosate exposure does not necessarily cause cancer in everyone exposed; individual factors like genetics, total cumulative exposure, duration of use, and protection measures all influence risk. A farmer who applied Roundup daily for 30 years without protective equipment faces different risk than someone who used it occasionally in a home garden, though both have pursued legal claims with varying success. The latency period—the time between exposure and cancer diagnosis—typically ranges from 5 to 20 years. This long timeline means many people who used Roundup during the 1980s and 1990s did not develop detectable cancer until the 2010s, by which time the scientific evidence had accumulated. This explains why verdicts and settlements have accelerated only in recent years despite glyphosate being in widespread use for over four decades.
How Strong Is the Scientific Evidence Compared to Regulatory Approval?
The strength of evidence behind Roundup cancer claims hinges on a significant disagreement between international health agencies and the U.S. Environmental Protection Agency. The IARC’s 2015 classification of glyphosate as “probably carcinogenic to humans” is based on a review of epidemiological studies, animal studies, and mechanistic evidence. This classification is published in the Lancet Oncology and is considered authoritative by most cancer research institutions worldwide. However, the EPA has repeatedly concluded that glyphosate is “not likely to be carcinogenic” at the exposure levels typical of agricultural and consumer use. This regulatory split is critical to understand: it does not mean the evidence is weak or that scientists are divided.
Rather, it reflects different thresholds for what constitutes actionable risk. The EPA’s assessment focuses on exposure at approved usage levels under current regulations, while the IARC examined the chemical itself and its potential to cause cancer at any exposure level. A limitation of the EPA’s approach is that it assumes people follow label instructions and protective protocols, which in practice many consumers and even agricultural workers do not. A homeowner who mixes Roundup in a garage without a respirator, or a farmer who refills sprayers without gloves, faces exposure far above what EPA models assume. Multiple lawsuits have revealed internal Monsanto documents—obtained through discovery—showing that the company was aware of glyphosate’s potential cancer risks decades before disclosing this information publicly. These documents have bolstered jury confidence in plaintiff claims and influenced verdicts. The combination of independent scientific evidence, internal company records, and jury findings has created a legal consensus that glyphosate poses a genuine cancer risk, regardless of the EPA’s continued regulatory stance.
What Are the Current Settlement Payouts and How Much Has Already Been Paid?
Bayer’s February 2026 settlement of $7.25 billion is specifically designed to resolve current and future non-Hodgkin’s lymphoma claims. Payouts under this settlement range from $6,000 to $165,000 per eligible claimant, depending on factors such as the severity of the plaintiff’s illness, the duration and intensity of Roundup exposure, age at diagnosis, and other medical circumstances. For context, a 55-year-old farmer diagnosed with stage III non-Hodgkin’s lymphoma after 25 years of occupational Roundup exposure might receive closer to the higher end of the range, while a 70-year-old with earlier-stage disease and less documented exposure might receive a mid-range award. Before this 2026 settlement, approximately 100,000 Roundup cancer claims had already been resolved through earlier settlements and jury verdicts, totaling roughly $11 billion in payouts. In July 2026 alone, Bayer settled an additional 60,000 lawsuits and announced $1.37 billion in additional spending for future payouts and legal costs.
This means that as of mid-2026, the total amount awarded or set aside for Roundup-related non-Hodgkin’s lymphoma claims exceeds $19 billion. Individual verdicts have varied widely: some juries have awarded $6 million to $8 million for single plaintiffs, while the 2025 Georgia verdict of $2 billion was exceptionally high and is currently under appeal. A practical limitation to understand is that settlement payouts are not guaranteed to equal jury verdicts. Most claims are resolved for substantially less than what a jury might award. This is because settlements avoid the risk and cost of trial, but plaintiffs accept lower amounts in exchange for certainty and speed. Additionally, attorney fees typically consume 25% to 33% of settlements, meaning a $50,000 settlement might result in $33,000 to $37,500 going directly to the claimant after legal costs.
How Many Roundup Lawsuits Are There, and How Many Remain Pending?
The scale of Roundup litigation is staggering. Approximately 170,000 total lawsuits have been filed against Bayer and Monsanto alleging Roundup-related non-Hodgkin’s lymphoma. Of these, about 100,000 claims have already been settled through various settlements over the past several years. In July 2026, an additional 60,000 claims were resolved, bringing the settled total to roughly 160,000. This leaves approximately 3,920 lawsuits pending in federal Multidistrict Litigation (MDL) #2741, though an additional estimated 58,000 claims are actively being pursued by claimants who have not yet joined the MDL or settled.
The distribution of these cases is important: roughly half have been resolved, while the other half remain in various stages of litigation. Some claimants are represented by individual attorneys, others by class action groups, and many are consolidated in the federal MDL system. The MDL allows hundreds or thousands of similar cases to be managed by one federal judge, which streamlines the legal process but also means individual claimants have less control over settlement terms than they would in a solo lawsuit. A comparison to other mass torts provides perspective on the scale: the tobacco litigation of the 1990s eventually resolved over 300,000 claims but took 25 years to conclude. The Roundup litigation, while already larger in total payouts, has moved faster due to the scientific evidence and jury verdicts being more definitive. However, the remaining cases could take several more years to resolve, especially if appeals continue.
What Did the Supreme Court’s June 2026 Ruling Mean for Pending Roundup Claims?
In June 2026, the U.S. Supreme Court ruled 7-2 in favor of Monsanto in a case questioning whether state-level tort lawsuits could require cancer warnings on Roundup products despite EPA approval. The ruling determined that federal EPA approval of glyphosate’s safety label supersedes state tort lawsuits seeking to impose additional warnings based on state law. This is a significant legal development that some observers initially interpreted as a blow to remaining Roundup claimants. However, the Supreme Court ruling does not eliminate existing claims or reverse the ability of juries to award damages based on the company’s failure to warn about known risks prior to the ruling.
Instead, it prevents future claimants from winning lawsuits based solely on the argument that Roundup should have carried a cancer warning at the point of sale. This is an important distinction: claimants who were exposed before the ruling, or whose claims were already filed, are not affected. The ruling mainly prevents new lawsuits going forward where the sole basis is “the warning label was inadequate.” It does not address whether Monsanto fraudulently concealed cancer risks or whether glyphosate itself caused harm. A warning for claimants considering remaining litigation: the Supreme Court ruling means that any new Roundup cancer claims filed after June 2026 face higher legal hurdles. Claims based on failure to warn are substantially weakened. This creates urgency for people who believe they have non-Hodgkin’s lymphoma from Roundup exposure to file or join existing claims before new legal precedent further limits their options.
What Were the Largest Individual Roundup Cancer Verdicts?
Jury verdicts in Roundup cases have reached extraordinary levels, particularly in cases involving long-term occupational exposure. In April 2025, a Georgia man received a $2 billion verdict after using Roundup for approximately 20 years in his yard and farm operations. The verdict was justified by the jury’s finding that Monsanto knew or should have known of glyphosate’s cancer risks but failed to warn consumers adequately.
This verdict remains under appeal and may be reduced by the court, but it illustrates the upper range of what juries believe appropriate compensation for decades of exposure and a terminal cancer diagnosis. In November 2025, a California appeals court affirmed a $28 million verdict for Mike Dennis, a former school groundskeeper who developed non-Hodgkin’s lymphoma after years of spraying Roundup to maintain school property. The appellate court’s affirmation is significant because it suggests that smaller verdicts in the millions of dollars range are likely to survive legal challenge, even if the $2 billion Georgia verdict is ultimately reduced. Other notable verdicts since October 2023 have included multiple eight-figure awards, with a total of over $6 billion awarded to plaintiffs across eight successful trials.
Who Can Claim the $7.25 Billion Settlement, and What Is the Deadline?
The February 2026 settlement covers two categories of claimants: those already diagnosed with non-Hodgkin’s lymphoma before February 17, 2026, and future claimants who will be diagnosed within 16 years after final court approval of the settlement. For current claimants, eligibility typically requires a confirmed non-Hodgkin’s lymphoma diagnosis, documented Roundup exposure history, and filing a claim form before the deadline. The deadline to join or formally opt out of the settlement was June 4, 2026. For future claimants, the settlement provides a mechanism to claim compensation at any point through at least 2042 (16 years after the anticipated 2026 settlement approval).
This addresses the latency issue in glyphosate-related cancer: someone who has been exposed recently may not develop cancer for another 10 or 15 years, but the settlement will still cover them if they meet the exposure and diagnosis criteria. The fairness hearing for the settlement was originally scheduled for July 9, 2026, but has been rescheduled to August 19, 2026, where a judge will determine whether the terms are fair to all claimants. Claimants who settled their cases individually before the February 2026 announcement generally cannot rejoin the settlement for additional compensation—they received their payout and relinquished their claim. This is a permanent trade-off of litigation: once settled, the case is closed.